ERBB2 and breast cancer: Drugs such as paclitaxel (antimitotic agent), lapatinib ditosylate (EGFR and ErbB‐2 dual tyrosine kinase inhibitor), and fluorouracil (DNA and RNA synthesis inhibitor) are FDA‐approved drugs for treating breast cancer that are included in our restart set, which were first mapped into our drug functional similarity network.